Nurses Nuria Sánchez and Paula Calvo, from the Clinical Trials Unit of the Marqués de Valdecilla University Hospital (HUMV/IDIVAL), have participated in an international study conducted within the framework of a clinical trial led by the Hematology Department. The results have just been published, providing the nursing staff’s perspective on a new drug delivery device for patients with multiple myeloma.
The study, titled “Subcutaneous Administration of Isatuximab in Patients With Multiple Myeloma by an OnBody Delivery System: Results of a Nurse Survey”, gathers the experience of nursing professionals from Spain, France, Germany, and Australia in the use of the OnBody Delivery System (OBDS) — a device that allows the subcutaneous administration of Isatuximab, improving patient comfort and reducing the workload for healthcare professionals.
According to the results, the surveyed professionals highlighted advantages such as ease of learning, time savings, the absence of visible needles, and the possibility of home administration compared to conventional intravenous or syringe-based subcutaneous routes. They also positively evaluated patients’ experiences, who reported good tolerance and satisfaction with the procedure.
This study originated as an initiative by Sanofi, the sponsor of one of the clinical trials conducted by the Valdecilla Clinical Trials Unit, who invited their nurses to collaborate in the design of the questionnaire and the subsequent publication of the results.
“It has been a great opportunity for us to take part in this study, contributing the perspective of nursing professionals in a key process to improve patient experience in hematology clinical trials,” explain Nuria Sánchez and Paula Calvo.
This work stands as an example of how collaboration between clinical trial nursing staff and the pharmaceutical industry can help optimize treatments and humanize care in oncohematology.
Link to the article: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1547108/full
Photo: Nuria Sánchez and Paula Calvo.
